DA
IMRX icon

DCF Advisers’s Immuneering IMRX Stock Holding History

DCF Advisers’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.94M Buy
790,000
+648,538
+458% +$3.28M 0.7% 28
2026
Q1 		$746K Sell
141,462
-73,538
-34% -$377K 0.2% 65
2025
Q4 		$1.41M Buy
+215,000
New +$1.38M 0.38% 59

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

DCF Advisers's IMRX Position: Q2 2026 in Review

DCF Advisers increased its Immuneering (IMRX) stake by 458% in Q2 2026, buying an estimated $3.28M and bringing the position to 790,000 shares worth $3.94M. The position accounts for 0.7% of the portfolio, ranked #28.

DCF Advisers first reported a position in IMRX in Q4 2025 and has held it in 3 quarters since. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • DCF Advisers held 790,000 shares of Immuneering worth $3.94M as of Q2 2026.
  • DCF Advisers bought 648,538 Immuneering shares in Q2 2026, an estimated $3.28M.
  • Immuneering made up 0.7% of DCF Advisers's portfolio in Q2 2026, its #28 holding.
  • DCF Advisers first reported a position in Immuneering in Q4 2025 and has held it in 3 quarters since.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.